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drocytes with regard to inﬂammation and its impact on metabolic activity.
Methods: Human chondrocytes were isolated from post-surgery dis-
carded human osteoarthritic articular cartilage. Expression of b2-adren-
ergic receptor on articular cartilage was tested with standard
immunohistochemical analysis. Employing 3D cell cultures in ﬁbringel,
effects of norepinephrine on interleukin-1b induced gene expression of
pro-inﬂammatory cytokines and matrix metalloproteinases (MMP) were
analyzed with quantitative real-time PCR. The impact of norepinephrine
on cell proliferation was determined in monolayer culture with BrdU and
XCelligence analyses.
Results: ß2-adrenergic receptors are abundantly expressed in human
osteoarthritic cartilage. Stimulation with norepinephrine has signiﬁcantly
reduced interleukin-1b induced gene expression of interleukin 8 and
MMP-13 in human osteoarthritic chondrocytes cultured in 3D ﬁbringel.
Notably, we were unable to detect an impact on interleukin-1b induced
gene expression of interleukin-6, MMP-2 and MMP-3. Furthermore,
norepinephrine inhibits BrdU incorporation compared to the controls.
Additionally, we measured a lower cell spreading, assessed through elec-
trical impedance using the XCelligence System (Roche), starting 6 h after
norepinephrine stimulation until analysis was stopped (50 h after stimu-
lation). All effects were observed exclusively with 10-6 M and not with 10-
8 M norepinephrine indicating for a signaling via b-adrenergic receptors.
Conclusions: Neurotransmitters of the sympathetic nervous system like
norepinephrine presumably mediate an anti-inﬂammatory / chon-
droprotective effect in human osteoarthritic chondrocytes via reducing
interleukin-8 and MMP-13. Furthermore, norepinephrine is able to
modulate the metabolic activity by inhibiting cell proliferation of human
osteoarthritic chondrocytes. These ﬁndings indicate, together with b2-
adrenergic receptor expression in human osteoarthritic articular cartilage,
a yet unknown function of catecholaminergic neurotransmitters in adult
human cartilage and might have an impact on osteoarthritis pathology.
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EGR-1 MEDIATES THE SUPPRESSIVE EFFECT OF IL-1 ON PPARG
EXPRESSION IN HUMAN OA CHONDROCYTES
S. Nebbaki, F. El Mansouri, N. Zayed, M. Benderdour, J. Martel-Pelletier,
J.-P. Pelletier, H. Fahmi. Univ. of Montreal, Montreal, QC, Canada
Purpose: PPARg has been shown to down-regulate several inﬂammatory
and catabolic responses in articular cartilage and chondrocytes and to be
protective in animal models of OA. We have previously shown that IL-1
down-regulated PPARg expression in OA chondrocytes. In the present
study we will investigate the mechanisms underlying this effect of IL-1.
Methods: Chondrocytes were stimulated with IL-1, and the level of PPARg
and Egr-1 protein and mRNA were evaluated using Western blotting and
real-time reverse-transcription polymerase chain reaction, respectively.
The PPARg promoter activity was analyzed in transient transfection
experiments. Egr-1 recruitment to the PPARg promoter was evaluated
using chromatin immunoprecipitation (ChIP) assays. Small interfering RNA
(siRNA) approaches were used to silence Egr-1 expression.
Results: We demonstrated that the suppressive effect of IL-1 on PPARg
expression requires de novo protein synthesis and was concomitant with
the induction of the transcription factor Egr-1. ChIP analyses revealed that
IL-1 induced Egr-1 recruitment at the PPARg promoter. IL-1 inhibited the
activity of PPARg promoter and overexpression of Egr-1 potentiated the
inhibitory effect of IL-1, suggesting that Egr-1 maymediate the suppressive
effect of IL-1. Finally, Egr-1 silencing with small interfering RNA blocked
IL-1-mediated down-regulation of PPARg expression.
Conclusion: These results indicate that Egr-1 contributes to IL-1-mediated
down-regulation of PPARg expression in OA chondrocytes and suggest that
this pathway could be a potential target for pharmacologic intervention in
the treatment of OA and possibly other arthritic diseases.
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THE FUNCTIONAL EFFECTS OF DIO2 IN AN IN-VITRO MODEL FOR
CHONDROGENESIS
N. Bömer 1, Y.F. Ramos 1, S.D. Bos 1,2, B.J. Duijnisveld 3, W. Koevoet 4,
G.J. van Osch 4,5, R.G. Nelissen 3, P.E. Slagboom1,2, I. Meulenbelt 1,2. 1Dept.of Molecular Epidemiology, LUMC, Leiden, Netherlands; 2 The Netherlands
Genomics Initiative-sponsored Netherlands Consortium for Hlth.y Aging
(NGI-NCHA), Leiden, Netherlands; 3Dept. of Orthopedics, LUMC, Leiden,
Netherlands; 4Dept. of Otorhinolaryngology, Erasmus MC, Rotterdam,
Netherlands; 5Dept. of Orthopedics, Erasmus MC, Rotterdam, Netherlands
Purpose: Previously, we identiﬁed the deiodinase iodothyronine type-2
gene (DIO2) as a relevant susceptibility gene for osteoarthritis (OA). The
type 2 deiodinase (D2) is a selenoprotein responsible for catalyzing the
conversion of intracellular inactive thyroid (T4) to active thyroid (T3),
a process that occurs in speciﬁc tissues including the growth plate. In the
growth plate, T3 speciﬁcally signals terminal maturation of the chon-
drocytes. Here, we investigate the role of DIO2 during chondrogenesis by
interfering with D2 protein function in an in-vitro chondrogenesis model.
Methods: The ‘RAAK’ study contains human bone marrow derived
mesenchymal stem cells (BM-MSCs) which were isolated from OA affected
hips joints of subjects undergoing total hip arthroplasty. These BM-MSCs
were cultured as micromasses and differentiated into cartilage particles.
First, we assessed expression of DIO2 at consecutive weeks of chondro-
genesis by RT-qPCR on samples previously isolated by the Rotterdam
departments. Next, we tested the RAAK samples for the effect of T3 and
Iodopanoic Acid (IOP), a DIO2 inhibitor, on chondrogenesis by adding them
to the chondrogenic culture medium of the micromass cultures. These
micromass cultures were than maintained up to 49 days. To measure the
effects of interfering with D2 protein function we initially assessed pellet
sizes at different time points and histochemistry with Alcian blue to
determine glycosaminoglycan and Alizarin red to determine calciﬁcations.
Results: DIO2 gene expression signiﬁcantly increased in untreated BM-
MSC micromasses during in-vitro chondrogenesis from 3 weeks onwards
of differentiation. Upon inhibition of DIO2 protein function with IOP, the
BM-MSC micromasses showed no signiﬁcant changes in size after 7 weeks
of differentiationwhen compared to untreated controls. In contrast, excess
of T3 resulted in signiﬁcantly smaller micromasses after 7 weeks of
differentiation suggesting decreased extracellular matrix deposition. This
observation was supported by histological analysis, which showed
decreased Alcian blue staining already after 5 weeks of differentiation in
T3 treated micromasses compared to untreated controls. In addition, only
upon treatment with T3, calcium deposition could be detected by Alizarin
Red staining from 5 weeks of differentiation onwards.
Conclusions: In addition to the association between DIO2 and osteoar-
thritis and the body of literature on the role of DIO2 in endochondral
ossiﬁcation, we are investigating the functional effect of DIO2 on chon-
drogenesis. Our ﬁrst results show a signiﬁcant up-regulation of DIO2 gene
expression during chondrogenic differentiation. Furthermore, we show
that excess T3 in this in-vitro chondrogenesis model, appears to interfere
with the chondrogenesis process reﬂected by signiﬁcant decreased pellet
sizes and decreased Alcian blue staining accompanied by increased
calcium deposition. Currently, we are using both lentiviral-induced DIO2
over expression and siRNA knock-down to explore directly the effect of
DIO2 interference during in-vitro chondrogenesis.
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EXPRESSION OF NUCLEOSTEMIN IN SYNOVIAL TISSUES AND IN
NORMAL AND OSTEOARTHRITIC CHONDROCYTES
M. Ricketts, D.M. Salter, S.H. Ralston. Univ. of Edinburgh, Edinburgh, United
Kingdom
Purpose: Osteoarthritis is a common disease with a strong genetic
component. Despite this, previous attempts to identify genetic variants
that predispose to osteoarthritis have met with limited success. In the past
few months, the results of a large genome wide association study for
osteoarthritis have been reported and identiﬁed a novel susceptibility
locus for the disease on chromosome 3 (Panoutsopoulou et al OARSI 2011).
The strongest association within this region was found with a SNP located
within the coding region of GNL3 gene which encodes nucleostemin
(p¼7.24x10-11). Nucleostemin is a protein that is found within the nucle-
olus of stem cells and tumour cells. It is thought to play a role in regulating
cell cycle progression by modulating the action of p53, but its role in the
joint is unknown. Here we wanted to determine if nucleostemin was
expressed in articular chondrocytes and other joint tissues to determine if
